AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06948396
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT06948747
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants
- First Posted Date
- 2025-04-28
- Last Posted Date
- 2025-04-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT06948006
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT06943833
- Locations
- 🇷🇺
Research Site, Yekaterinburg, Russian Federation
A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants
Phase 1
Not yet recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT06942936
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06942923
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
Phase 2
Recruiting
- Conditions
- Chronic Kidney Disease With High Proteinuria
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 224
- Registration Number
- NCT06942910
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 540
- Registration Number
- NCT06932263
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT06929260
CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 130
- Registration Number
- NCT06927648
© Copyright 2025. All Rights Reserved by MedPath